C
Concetta Rafaniello
Researcher at Seconda Università degli Studi di Napoli
Publications - 84
Citations - 1845
Concetta Rafaniello is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Pharmacovigilance & Medicine. The author has an hindex of 21, co-authored 64 publications receiving 1346 citations.
Papers
More filters
Journal ArticleDOI
Current pharmacological treatments for COVID-19: What's next?
Cristina Scavone,Simona Brusco,Michele Bertini,Liberata Sportiello,Concetta Rafaniello,Alice Zoccoli,Liberato Berrino,Giorgio Racagni,Francesco Rossi,Francesco Rossi,Annalisa Capuano +10 more
TL;DR: The main pharmacological properties of such drugs administered to patients with COVID‐19, focusing on their antiviral, immune‐modulatory and/or anti‐inflammatory actions are described.
Journal ArticleDOI
Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis
Katherine Esposito,Paolo Chiodini,Annalisa Capuano,Giuseppe Bellastella,Maria Ida Maiorino,Concetta Rafaniello,Demosthenes B. Panagiotakos,Dario Giugliano +7 more
TL;DR: A systematic review and meta-analysis of the empirical evidence on the association of metabolic syndrome and its components with colorectal cancer incidence and mortality found dysglycemia and/or higher BMI/waist explained most of the risk associated with metabolic syndrome.
Journal ArticleDOI
Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis.
Katherine Esposito,Paolo Chiodini,Annalisa Capuano,Giuseppe Bellastella,Maria Ida Maiorino,Concetta Rafaniello,Dario Giugliano +6 more
TL;DR: No single component explains the risk conveyed by the full syndrome, and MS is associated with a moderately increased risk of postmenopausal breast cancer.
Journal ArticleDOI
SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment.
TL;DR: The importance of sensitive and specific rapid test for SARS-CoV-2 represents an important immunological tool aimed at identifying the precise phase of the infection in order to undertake a more appropriate pharmacological treatment.
Journal ArticleDOI
Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.
Donato Cappetta,Grazia Esposito,Raffaele Coppini,Elena Piegari,Rosa Russo,Loreta Pia Ciuffreda,Alessia Rivellino,Lorenzo Santini,Concetta Rafaniello,Cristina Scavone,Francesco Rossi,Liberato Berrino,Konrad Urbanek,Antonella De Angelis +13 more
TL;DR: This study tested whether the administration of ranolazine, a selective blocker of late Na+ current, immediately after completing doxorubicin therapy, could affect diastolic dysfunction and interfere with the progression of functional decline.